Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07356089 · ClinicalTrials.gov registry record
Twiist Postmarket Surveillance Study for Type 1 Diabetes
A clinical trial of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), sponsored by Deka Research and Development.
- Recruiting
- Registry status
- 1,875
- Enrollment target
- 1
- Study location
NCT07356089: Recruiting study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), sponsored by Deka Research and Development.
NCT07356089 is a study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D) that is actively recruiting participants, run by Deka Research and Development. The registered enrollment target is 1,875 participants, above the 155-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (1110% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07356089, a study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), is actively recruiting participants, sponsored by Deka Research and Development.
- RECRUITING
- Registry status
- 1,875 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
Primary Outcome
Severe hypoglycemia events with cognitive impairment sufficient to require the assistance of a third party for treatment
Conditions Studied
Interventions
- DEVICE twiist Automated Insulin Delivery System
Study Locations (1)
Florida
- Jaeb Center for Health Research - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,875 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2028-05-01 |
What NCT07356089 shows while recruiting
NCT07356089 is an observational study that tracks outcomes without assigning an intervention. Its 1,875 participants enrollment target places it among the larger protocols in the corpus, above the 155-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (1110% higher).
The record links to 2 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which twiist Automated Insulin Delivery System is the first listed.
NCT07356089 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07356089 about?
NCT07356089 is a clinical study titled "Twiist Postmarket Surveillance Study for Type 1 Diabetes". The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
What is the current status of trial NCT07356089?
This trial is currently recruiting. The enrollment target is 1,875 participants. The study started on 2025-12-09. Estimated completion is 2028-05-01.
What conditions does trial NCT07356089 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D).
What interventions are being tested in trial NCT07356089?
The interventions under investigation include: twiist Automated Insulin Delivery System (DEVICE).
Who is sponsoring clinical trial NCT07356089?
This trial is sponsored by Deka Research and Development, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07356089 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07356089's enrollment target sits among peer trials
1,875 2nd of 112 the highest of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI